Authors:
T Forshew, M Murtaza, C Parkinson, D Gale, DWY Tsui, F Kaper, S-J Dawson, AM Piskorz, M Jimenez-Linan, D Bentley, J Hadfield, AP May, C Caldas, JD Brenton, N Rosenfeld
Journal name: 
Sci Transl Med
Citation info: 
4(136):136ra68
Abstract: 
Plasma of cancer patients contains cell-free tumor DNA that carries information on tumor mutations and tumor burden. Individual mutations have been probed using allele-specific assays, but sequencing of entire genes to detect cancer mutations in circulating DNA has not been demonstrated. We developed a method for tagged-amplicon deep sequencing (TAm-Seq) and screened 5995 genomic bases for low-frequency mutations. Using this method, we identified cancer mutations present in circulating DNA at allele frequencies as low as 2%, with sensitivity and specificity of >97%. We identified mutations throughout the tumor suppressor gene TP53 in circulating DNA from 46 plasma samples of advanced ovarian cancer patients. We demonstrated use of TAm-Seq to noninvasively identify the origin of metastatic relapse in a patient with multiple primary tumors. In another case, we identified in plasma an EGFR mutation not found in an initial ovarian biopsy. We further used TAm-Seq to monitor tumor dynamics, and tracked 10 concomitant mutations in plasma of a metastatic breast cancer patient over 16 months. This low-cost, high-throughput method could facilitate analysis of circulating DNA as a noninvasive "liquid biopsy" for personalized cancer genomics.
DOI: 
http://doi.org/10.1126/scitranslmed.3003726
Research group: 
Caldas Group, Brenton Group, Rosenfeld Group
E-pub date: 
30 May 2012